Warner Chilcott Company, Inc. announced today that it has received a Paragraph IV Certification Notice from Watson Laboratories, Inc. advising of the filing of an Abbreviated New Drug Application (ANDA) for a generic version of LOESTRIN(R) 24 FE.
Drug
Newswire
Simplifying Global Compliance
Recommended Products
GMP Inspection Preparation Checklist: A Tool for Internal Auditing
This management report includes more than 650 items organized in three sections covering all aspects of quality manufacturing.
Biological Risk Evaluation and Management for Medical Devices
Report shows how the FDA incorporates the two ISO standards in its medical device development policy, how the EU version of the two standards differs in significant ways and how the EU Medical Device Regulation may require further changes in the European standards.
Editor's Picks
LumiThera’s Dry AMD Treatment Device Gains CE Mark
The treatment incorporates low level light therapy, applying red and near-infrared light to improve and repair tissue.
Consumer Group Calls for Withdrawal of Takeda’s Gout Treatment
A post-market clinical trial found higher all-cause and cardiovascular mortality in febuxostat-exposed subjects.
FDAnews Drug Daily Bulletin
WARNER CHILCOTT ANNOUNCES RECEIPT OF PARAGRAPH IV CERTIFICATION NOTICE
June 28, 2006